Results 11 to 20 of about 43,876 (313)

Donepezil Ameliorates Pulmonary Arterial Hypertension by Inhibiting M2-Macrophage Activation

Frontiers in Cardiovascular Medicine, 2021
Background: The beneficial effects of parasympathetic stimulation in pulmonary arterial hypertension (PAH) have been reported. However, the specific mechanism has not been completely clarified.
Haihua Qiu, Yibo Zhang, Zhongyun Li, Ping Jiang, Shuhong Guo, Yi He, Yuan Guo   +6 more
semanticscholar   +1 more source

A meta‐analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil

International Journal of Geriatric Psychiatry, 2021
Physical exercise may benefit people with Alzheimer's disease (AD) and mild cognitive impairment (MCI). However, randomised controlled trials (RCTs) of exercise have shown conflicting findings and it is unclear if positive outcomes are comparable to a ...
S. Pisani, C. Mueller, Jonathan Huntley, D. Aarsland, M. Kempton   +4 more
semanticscholar   +1 more source

Cognitive Enhancer Donepezil Attenuates Heroin-Seeking Behavior Induced by Cues in Rats

Journal of Integrative Neuroscience, 2023
Purpose: Opioid use disorder is a significant global problem. Chronic heroin use is associated with impairment of cognitive function and conscious control ability.
Disen Mei, Fangmin Wang, Bo Yuan, Miaojun Lai, Yiying Zhou, Wei Cui, Huifen Liu, Wenhua Zhou   +7 more
doaj   +1 more source

Donepezil for mild cognitive impairment in Parkinson’s disease

Scientific Reports, 2021
We investigated the efficacy of donepezil for mild cognitive impairment in Parkinson’s disease (PD-MCI). This was a prospective, non-randomized, open-label, two-arm study. Eighty PD-MCI patients were assigned to either a treatment or control group.
Kyoungwon Baik, Seon Myeong Kim, Jin Ho Jung, Yang Hyun Lee, S. Chung, H. S. Yoo, B. S. Ye, P. Lee, Y. Sohn, Seung Wan Kang, S. Kang   +10 more
semanticscholar   +1 more source

Nootropics use in the workplace. Psychiatric and ethical aftermath towards the new frontier of bioengineering [PDF]

, 2020
OBJECTIVE: The authors have sought to expound upon and shed a light on the rise of nootropics, which have gradually taken on a more and more relevant role in workplaces and academic settings.
Bersani, G, Ciallella, C, Del Rio, A, Marinelli, E, Rinaldi, Raffaella, Zaami, S   +5 more
core   +1 more source

Memantine, Donepezil, or Combination Therapy—What is the best therapy for Alzheimer’s Disease? A Network Meta‐Analysis

Brain and Behavior, 2020
Alzheimer's disease (AD) is a degenerative brain disease that progresses over time, heavily burdening patients, families, and aging societies worldwide. Memantine and donepezil are frequently used in its treatment, both as monotherapy and in combination.
Jiaxun Guo, Zhenyu Wang, Ruishu Liu, Yunxia Huang, Nan Zhang, Ruihan Zhang   +5 more
semanticscholar   +1 more source

ApoE-Targeting Increases the Transfer of Solid Lipid Nanoparticles with Donepezil Cargo across a Culture Model of the Blood–Brain Barrier

Pharmaceutics, 2020
Pharmacological treatment of central nervous system (CNS) disorders is difficult, because the blood–brain barrier (BBB) restricts the penetration of many drugs into the brain. To solve this unmet therapeutic need, nanosized drug carriers are the focus of
Gizem Rüya Topal, M. Mészáros, G. Porkoláb, Anikó Szecskó, T. Polgár, L. Siklós, M. Deli, S. Veszelka, A. Bozkır   +8 more
semanticscholar   +1 more source

Effect of QT Prolongation in Patients Taking Cholinesterase Inhibitors (Donepezil) for Alzheimer’s Disease

Circulation Reports, 2021
Background: Cholinesterase inhibitors such as donepezil are used in the treatment of Alzheimer’s disease. Patients taking cholinesterase inhibitors can develop cholinergically mediated QT prolongation, which may lead to life-threatening arrhythmias.
So Kuwahata, T. Takenaka, T. Motoya, Keisuke Masuda, Hideyuki Yonezawa, Shuya Shinchi, Y. Kawashima, Shogo Mohri, M. Ohishi   +8 more
semanticscholar   +1 more source

Stereoselective metabolism of donepezil and steady-state plasma concentrations of S-donepezil based on CYP2D6 polymorphisms in the therapeutic responses of Han Chinese patients with Alzheimer's disease

Journal of Pharmacological Sciences, 2015
The therapeutic response rates of patients to donepezil vary from 20% to 60%, one of the reasons is their genetic differences in donepezil-metabolizing enzymes, which directly influence liver metabolism. However, the mechanism of donepezil metabolism and
Jin Lu, Lili Wan, Yuan Zhong, Qi Yu, Yonglong Han, Pengguo Chen, Beiyun Wang, Wei Li, Ya Miao, Cheng Guo   +9 more
doaj   +1 more source

Postoperative Administration of the Acetylcholinesterase Inhibitor, Donepezil, Interferes with Bone Healing and Implant Osseointegration in a Rat Model

Biomolecules, 2020
Donepezil is an acetylcholinesterase inhibitor commonly used to treat mild to moderate Alzheimer’s disease. Its use has been associated with increased bone mass in humans and animals.
Faez Saleh Al-Hamed, Ola M. Maria, Jeff Phan, Ahmed Al Subaie, Qiman Gao, Alaa Mansour, Lina Abu Nada, Imane Boukhatem, Osama A. Elkashty, Simon D. Tran, Marie Lordkipanidzé, Zahi Badran, Faleh Tamimi   +12 more
doaj   +1 more source